U.S. Diversified Financial Stock News

NYSE:FLO
NYSE:FLOFood

What Do Insider Trades Tell Us About Flowers Foods?

In the last twelve months insiders purchased 12.46k shares for US$207k. On the other hand they divested 562.60k shares, for US$6.8m. In total, Flowers Foods insiders sold more than they bought over the last year (this includes transactions on indirectly owned stock where the insiders do not have full control over the trading decisions).
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

Is It Time To Reassess National Vision Holdings (EYE) After Its 150% One Year Surge

If you are wondering whether National Vision Holdings is still good value after its recent run, looking closely at what the current share price implies can help you set realistic expectations. The stock last closed at US$26.34, with returns of 1.5% over the past week, an 8.6% decline over the past 30 days, 1.5% year to date, a 150.4% gain over the past year, a 35.0% decline over three years, and a 45.8% decline over five years. This combination paints a mixed picture for anyone thinking...
NYSE:BIPC
NYSE:BIPCGas Utilities

Brookfield Infrastructure (NYSE:BIPC) Valuation Check After Recent Share Price Pullback

Brookfield Infrastructure stock snapshot Brookfield Infrastructure (BIPC) shares have retreated over the past month and past 3 months, with the stock closing at US$43.26. This may prompt investors to reassess the company’s current valuation and fundamentals. See our latest analysis for Brookfield Infrastructure. BIPC’s recent 1 month share price return of a 6.63% decline and 3 month share price return of a 5.07% decline contrast with a 1 year total shareholder return of 18.58%, suggesting...
NasdaqGM:SIBN
NasdaqGM:SIBNMedical Equipment

What SI-BONE (SIBN)'s 'Great, Great Speculation' Media Buzz Means For Shareholders

In recent days, Jim Cramer repeatedly described SI-BONE as a “great, great speculation” on air, drawing attention to its minimally invasive sacropelvic implants and broader musculoskeletal device portfolio. His comments, combined with fresh analyst coverage and insider sales tied to tax withholding and Rule 10b5-1 plans, have sharpened focus on how media visibility, governance practices, and medical device innovation intersect for this company. Next, we’ll examine how Cramer’s “great, great...
NasdaqCM:AXG
NasdaqCM:AXGCapital Markets

Solowin Holdings (AXG) Loss Profile Reinforces Bearish Narratives Despite Revenue Progress

Solowin Holdings (NasdaqCM:AXG) has released its H1 2026 scorecard with trailing 12 month revenue of US$7.7 million and a net loss of US$6.9 million, against a current share price of US$4.18. The company has seen revenue move from US$0.95 million in H2 2024 to US$1.47 million in H1 2025 and US$1.85 million in H2 2025, while basic EPS over those periods shifted from a loss of US$0.38 per share to a loss of US$0.39 and then a smaller loss of US$0.14. For investors, a key consideration is how...
NYSEAM:GPUS
NYSEAM:GPUSIndustrials

Is Hyperscale Data’s (GPUS) Aggressive Bitcoin Treasury Strategy Redefining Its Core Investment Narrative?

Hyperscale Data, Inc. recently filed an US$8.60 million shelf registration for up to 43,011,836 shares of Class A common stock and confirmed CBIZ CPAs P.C. as its auditor for fiscal 2025, while outlining preliminary year-end asset estimates including cash and Bitcoin holdings. The company’s decision to build a very large Bitcoin treasury relative to its market value, combined with frequent asset-disclosure updates and insider buying, has become a central feature of its evolving investment...
NasdaqGS:INMD
NasdaqGS:INMDMedical Equipment

Updated 2025–2026 Revenue Guidance Might Change The Case For Investing In InMode (INMD)

InMode Ltd. recently issued updated earnings guidance, projecting fourth-quarter 2025 revenue of about US$103.6 million to US$103.8 million, full-year 2025 revenue of roughly US$370.2 million to US$370.4 million, and full-year 2026 revenue of US$365 million to US$375 million. This guidance gives investors a clearer view of InMode’s expected revenue trajectory over the next two years, which can be weighed against prior expectations for moderating earnings and margin compression in its...
NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

Is SIGA Technologies’ (SIGA) TPOXX Cash Machine Reinforcing a Deep-Value Biodefense Narrative?

In recent commentary, SIGA Technologies has been highlighted as a niche biodefense pharmaceutical company with a highly profitable TPOXX antiviral franchise, a strong balance sheet, and contracts primarily with government agencies for smallpox treatment. An interesting angle is how SIGA’s combination of substantial free cash flow, minimal debt, and focus on a single government-backed product is shaping its appeal as a perceived deep-value biodefense play. Next, we’ll examine how SIGA’s...